Lodewyk Wessels
Professor
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (39)
Studies have identified a link between specific microbiome-derived bacteria and immune checkpoint blockade (ICB) efficacy. However, these species lack consistency across studies, and their immunomodulatory mechanisms remain elusive. To understand the influence of the microbiome on ICB response, we studied its functional capacity. Using pan-cancer metagenomics data from ICB-treated patients, we showed that community-level metabolic pathways are stable across individuals, making them suitable for predicting ICB response. We identified several microbial metabolic processes significantly associated with response, including the methylerythritol 4-phosphate (MEP) pathway, which was associated with response and induced Vδ2 T cell–mediated antitumor responses in patient-derived tumor organoids. In contrast, riboflavin synthesis was associated with ICB resistance, and its intermediates induced mucosal-associated invariant T (MAIT) cell–mediated immune suppression. Moreover, gut metabolomics revealed that high riboflavin levels were linked to worse survival in patients with abundant intratumoral MAIT cells. Collectively, our results highlight the relevance of metabolite-mediated microbiome–immune cell cross-talk. Significance: Microbial metabolic pathways are highly conserved across individuals and therefore offer an opportunity to link the microbiome to immunotherapy efficacy. We identified specific microbial metabolic pathways associated with response to ICB and provided mechanistic insights into the immunomodulatory influence of these pathways on antitumor immunity.
Year:
2026
Zinc finger proteins (ZNFs) are the largest family of transcription factors, yet how they activate gene expression remains unclear. In this study, we identified Zincore, a protein complex consisting of QRICH1 and SEPHS1, as a ZNF-specific coregulator essential for embryonic development in mice and associated with developmental syndromes in humans. We also identified ZFP91 as a representative Zincore client, binding the conserved promoter motif CTTTAAR. Cryo–electron microscopy of a Zincore-ZFP91-DNA complex revealed a SEPHS1 arginine clamp to recognize the DNA-bound zinc finger domains. This mode of binding explains recognition of different ZNFs and stabilizes ZFP91 onto its cognate DNA motif. Thus, our study identified Zincore as a ZNF-specific coregulator essential for development, involving a distinctive mechanism that locks ZNFs onto DNA and regulates transcription.
Year:
2025
Perturbation response models (PRMs) predict transcriptional responses to interventions such as gene knockout or drug treatments. While simple baseline models match PRMs in reconstructing post-treatment profiles, we show that drug response predictors trained on PRM-generated profiles significantly outperform those trained on baseline or pre-treatment profiles. Unlike simple baseline models, PRMs preserve variation in response-relevant genes, making them a highly valuable tool for predicting drug response.
Year:
2025
Silencing of apoptotic pathway genes confers resistance to agonists of the death receptor pathway. Volcano plots of genes enriched or depleted for gRNA when rTRAIL-treated cells were compared with DMSO vehicle control cells following transduction with a genome-wide CRISPR/Cas9 library in MSTO-211H mesothelioma ( A ) and PC-9 lung adenocarcinoma ( B ) cells. Each dot represents gene-wise scores for MAGeCK gene level analysis with genes of interest highlighted. The dotted line indicates an FDR of 0.1. x -axis, log 2 fold change of mean gRNA reads per genes comparing treatment to DMSO replicates. y -axis, −log 10 FDR for genes based upon their negative (pink and red dots) and positive (blue dots) fold change and FDR calculated by the MAGeCK algorithm. C, Confirmation of deletion of target apoptotic genes following transfection with synthetic crRNA in MSTO-211H, NCI-H28, and H2804 cancer cells. D, Six-day viability assay in MSTO-211H cells following deletion of specific apoptotic genes and treatment with either rTRAIL or MEDI3039. y -axis: viability effect relative to control cells. E, Volcano plots as in A and B illustrating results of SAM CRISPR activatory screen in PC-9 cells treated with rTRAIL. F, MSTO-211H isogenic cell lines were screened versus the parental cell line with a concentration range of 60 compounds and viability measured at day 6. The AUC values for each isogenic cell line and the matched parental Cas9 line were subtracted to calculate a ΔAUC value, with high (positive) values indicating increased resistance to that compound in the isogenic lines, and low (negative) values increased sensitivity. x -axis: name of compounds screened. y -axis: ΔAUC values.
Year:
2025
In vivo expression of CASP8 and CFLAR (FLIP) modulate response to MEDI3039 in PDX models. A, Change in percent tumor growth from baseline was measured at day 18 in 18 CRC PDX models treated with a fixed dose of MEDI3039. B, Tumor plots of responder, nonresponder, and partial response models. x -axis, days; y -axis, tumor volume. Arrows indicate treatment with MEDI3039. Red line, MEDI039-treated mice; blue line, untreated mice. C, Tumor CASP8 mRNA expression in PDX nonresponders (red) and responders (blue) with MEDI3039 (each circle represents a tumor from a single mouse). D, Comparison of CASP8:CFLAR ratio in MEDI3039 responder (blue) and nonresponder (red) PDX models.
Year:
2025
MEDI3039 sensitivity is significantly affected by FLIP(L)–caspase-8 ratio. A, Percentage cell death at 24 hours post MEDI3039 10 pmol/L in a panel of colorectal cell lines. B, Scatter plot of summary correlation analysis of cell death protein expression and percent cell death induced in response to MEDI3039 across panel of colorectal cancer cell lines. C, CASP8/FLIP or CASP8/MCL1 ratio protein expression versus MEDI3039-induced cell death. Each circle indicates a cell line. MEDI3039 AUC for cell lines for different cell types split according to discretized CASP8/FLIP ( D ) or CASP8/MCL1 ( E ) ratio (mRNA expression).
Year:
2025
Sensitivity of cancer cell lines to MEDI3039. A panel of 758 cancer cell lines was treated for 6 days with a concentration range of the death receptor agonist MEDI3039 and viability measured as AUC. A, Frequency distribution plot illustrating bimodal distribution of MEDI3039 AUC values for solid (green) and hematopoietic (blue) cell lines. B, AUC values with SD error bars for each cell line (circles) in 19 tissue types and individually colored according to high or low CASP8 mRNA expression as defined by the bimodal mid-point. C, Plot of cell line expression of most significant CASP8 microarray probeset ranked on the basis of sensitivity to MEDI3039. D, A two-tailed t test was calculated for 30 tissue types using MEDI3039 AUC values and CASP8 expression, and the P value indicated ( E ) predictive 9 probeset (7 gene) predictive geneset identified by vSURF random forest analysis of microarray data. F, AUC plot demonstrating ability of 9 probeset predictive geneset to classify solid cell lines as “sensitive” or “resistant.” See Supplementary Fig. S2B for description of cancer type abbreviations used in B and D .
Year:
2025
Drug combinations to overcome rTRAIL resistance in isogenic cell lines. A, Isogenic MSTO-211H cell lines were screened against 59 compounds in combination with a fixed dose of MEDI3039 (100 pmol/L). Viability was measured at day 6. For each combination, a ΔAUC was calculated by subtracting the observed from the expected AUC (based upon the activity of the MEDI3039 concentration as a single agent). Values >0.2 are indicative of synergy. x -axis: name of compounds screened. Bid-KO MSTO-211H or Bid-mutant Sup-T1 cells were treated with a concentration range of the IAP inhibitor AZD5582 ( B ) or LCL161 ( C ) for 6 days (blue line) or in combination with a fixed concentration of MEDI3039 (green, IC 90 values of parental cell line). Indicated is the effect of the fixed concentration of MEDI3039 (red dotted) and the expected (additive) effect of the combination (gray dotted). x -axis: log 10 scale concentration range. y -axis: relative viability effect. D, Clonogenic survival assays at day 14 in Cas9 versus crBID MSTO-211H and PC-9 cells treated with the indicated IAP inhibitors AZD and LCL161 as single agents or combined with MEDI3039. AZD, AZD5582. E, Annexin V/PI staining of Cas9 versus BID KO MSTO-211H and PC-9 cells following 24-hour treatment with MEDI3039 ±10 nmol/L AZD5582.
Year:
2025
Immune checkpoint blockade has led to paradigm shifts in the treatment of various tumour types 1–4 , yet limited efficacy has been observed in patients with metastatic mismatch-repair-proficient (pMMR) colorectal cancer 5 . Here we report clinical results and in-depth analysis of patients with early-stage pMMR colon cancer from the phase II NICHE study (ClinicalTrials.gov: NCT03026140). A total of 31 patients received neoadjuvant treatment of nivolumab plus ipilimumab followed by surgery. The response rate was 26% and included six patients with a major pathological response (10% or less residual viable tumour). One patient with an ongoing clinical complete response did not undergo surgery. Circulating tumour DNA was positive in 26 of 31 patients at baseline, and clearance was observed in 5 of 6 responders before surgery, whereas 19 of 20 non-responders remained circulating tumour DNA positive. Responses were observed despite a low tumour mutational burden in all tumours, whereas chromosomal genomic instability scores were significantly higher in responders than in non-responders. Furthermore, responding tumours had significantly higher baseline expression of proliferation signatures and TCF1, and imaging mass cytometry revealed a higher percentage of Ki-67 + cancer and Ki-67 + CD8 + T cells in responders than in non-responders. These results provide a comprehensive analysis of response to neoadjuvant immune checkpoint blockade in early-stage pMMR colon cancers and identify potential biomarkers for patient selection.
Year:
2025
Studies have identified a link between specific microbiome-derived bacteria and immune checkpoint blockade (ICB) efficacy. However, these species lack consistency across studies, and their immunomodulatory mechanisms remain elusive. To understand the influence of the microbiome on ICB response, we studied its functional capacity. Using pan-cancer metagenomics data from ICB-treated patients, we showed that community-level metabolic pathways are stable across individuals, making them suitable for predicting ICB response. We identified several microbial metabolic processes significantly associated with response, including the methylerythritol 4-phosphate (MEP) pathway, which was associated with response and induced Vδ2 T cell–mediated antitumor responses in patient-derived tumor organoids. In contrast, riboflavin synthesis was associated with ICB resistance, and its intermediates induced mucosal-associated invariant T (MAIT) cell–mediated immune suppression. Moreover, gut metabolomics revealed that high riboflavin levels were linked to worse survival in patients with abundant intratumoral MAIT cells. Collectively, our results highlight the relevance of metabolite-mediated microbiome–immune cell cross-talk. Significance: Microbial metabolic pathways are highly conserved across individuals and therefore offer an opportunity to link the microbiome to immunotherapy efficacy. We identified specific microbial metabolic pathways associated with response to ICB and provided mechanistic insights into the immunomodulatory influence of these pathways on antitumor immunity.
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Collaborators (42)
John Ladbury
Professor and Director of Leeds Centre for Disease Models
University of Leeds
Britt Suelmann
University Medical Center Utrecht, Utrecht University
Katarzyna Joanna Jerzak
University of Toronto
Marcel Reinders
Delft University of Technology
Maarten Altelaar
Professor
Utrecht University
Boudewijn Burgering
University Medical Center Groningen
Joachim G. Aerts
head of department
Erasmus MC
Patrick Neven
University Hospitals Leuven
Kristel Van Calsteren
KU Leuven
Niven Mehra
Group Leader
Radboud University Medical Center
Klaas Mulder
Tenured Group Leader - Associate Professor
Radboud University
Diether Lambrechts
Science Director
KU Leuven
Richard Meijer
Professor; Head Dept Oncological Urology
University Medical Center Groningen
Carla M.L. van Herpen
Radboud University Medical Center
Adriaan D. Bins
-
Daniel Longley
The Queen's University Belfast
Krijn Dijkstra
The Netherlands Cancer Institute
Patrick Celie
head of facility
Antoni van Leeuwenhoek Nederlands Kanker Instituut
Ann Hoeben
Maastricht University Medical Centre
Kim Monkhorst
The Netherlands Cancer Institute
Ton Schumacher
Principal Investigator
Oncode Institute
Evert Bosdriesz
Assistant professor
University of Amsterdam
Marieke van de Ven
Head of Mouse Cancer Clinic
-
Marleen Kok
Principal Investigator
The Netherlands Cancer Institute
Henk Verheul
Professor of Medical Oncology
Erasmus MC
Noel de Miranda
Professor
Leiden University Medical Center
Frédéric Amant
Antoni van Leeuwenhoek Nederlands Kanker Instituut
Mariette Labots
VU medisch centrum
John Haanen
Chair of Translational Immunotherapy of Cancer
Leiden University Medical Center
Catrin Lutz
The Netherlands Cancer Institute
Anastassis Perrakis
Principal Investigator
Antoni van Leeuwenhoek Nederlands Kanker Instituut
Ellen Warner
University of Toronto
Marcel de Zoete
University Medical Center Groningen
Magali Michaut
Københavns Universitet
Hans Gelderblom
Prof.dr
Leiden University Medical Center
Corinna Ernst
Hannover Medical School
Charlotte Maggen
Vrije Universiteit Brussel
Egbert Smit
Leiden University Medical Center
Jochen Prehn
Royal College of Surgeons in Ireland
Simon McDade
The Queen's University Belfast
Fedro Peccatori
Director, Fertility nd Procreation in Oncology Unit
European Institute of Oncology
Michiel Vermeulen
Senior group leader
Radboud Universiteit Nijmegen
Make your next move.
Prepare your application
Review drafts before you send them.